LymphedemaV1, PubMed, Corpus, bibRecord, 001291

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Identifieur interne : 001291 ( PubMed/Corpus ); précédent : 001290; suivant : 001292

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Auteurs : Victor Pernin ; Lisa Belin ; Paul Cottu ; Patrick Bontemps ; Claire Lemanski ; Brigitte De La Lande ; Pierre Baumann ; Fernand Missohou ; Christelle Levy ; Karine Peignaux ; Pierre Bougnoux ; Fabrice Denis ; Marc Bollet ; Rémi Dendale ; Nora Ady Vago ; François Campana ; Alain Fourquet ; Youlia M. Kirova

Source :

Breast (Edinburgh, Scotland) [ 1532-3080 ] ; 2014.

RBID : pubmed:25260760

English descriptors

KwdEn :
- Adult, Aged, Angiogenesis Inhibitors (adverse effects), Antibodies, Monoclonal, Humanized (adverse effects), Bevacizumab, Breast Neoplasms (pathology), Breast Neoplasms (therapy), Carcinoma, Ductal, Breast (pathology), Carcinoma, Ductal, Breast (therapy), Carcinoma, Lobular (pathology), Carcinoma, Lobular (therapy), Chemoradiotherapy, Adjuvant (adverse effects), Dermatitis (etiology), Dyspnea (etiology), Esophagitis (etiology), Female, Fibrosis, Humans, Lymphedema (etiology), Middle Aged, Neoadjuvant Therapy, Prospective Studies, Radiation Injuries (etiology), Radiation-Sensitizing Agents (adverse effects), Skin (pathology), Telangiectasis (etiology).
MESH :
- chemical , adverse effects : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Radiation-Sensitizing Agents.
- adverse effects : Chemoradiotherapy, Adjuvant.
- etiology : Dermatitis, Dyspnea, Esophagitis, Lymphedema, Radiation Injuries, Telangiectasis.
- pathology : Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Skin.
- therapy : Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular.
- Adult, Aged, Bevacizumab, Female, Fibrosis, Humans, Middle Aged, Neoadjuvant Therapy, Prospective Studies.

Abstract

The purpose of this multicenter prospective and descriptive study was to determine late toxicities and outcomes among patients with non-metastatic breast cancer receiving concurrent bevacizumab (BV) and radiation therapy (RT) in the clinical trials. Early and late toxicities were assessed and evaluation was available for 63 patients (pts) at 12 months. Acute radiation dermatitis was observed in 48 (76%): grade 1 for 27, grade 2 for 17 and grade 3 for 4 pts. Grade 2 acute oesophagitis was observed in one patient (2%). Little toxicity was described 1 year after the completion of RT: 7 pts (12%): grade 1-2 pain, 3 (5%) presented grade 1 fibrosis, and 2 pts (4%) - telangiectasia. One patient (2%) experienced grade 1 dyspnoea. Five grade 1-2 lymphoedema occurred. Only one patient experienced a LEVF value less than 50% one year after the end of RT. In conclusion, the concurrent BV with locoregional RT provides acceptable toxicities.

DOI: 10.1016/j.breast.2014.08.015
PubMed: 25260760

Links to Exploration step

pubmed:25260760

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.</title>
<author><name sortKey="Pernin, Victor" sort="Pernin, Victor" uniqKey="Pernin V" first="Victor" last="Pernin">Victor Pernin</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Belin, Lisa" sort="Belin, Lisa" uniqKey="Belin L" first="Lisa" last="Belin">Lisa Belin</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Biostatistic Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cottu, Paul" sort="Cottu, Paul" uniqKey="Cottu P" first="Paul" last="Cottu">Paul Cottu</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Oncology Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bontemps, Patrick" sort="Bontemps, Patrick" uniqKey="Bontemps P" first="Patrick" last="Bontemps">Patrick Bontemps</name>
<affiliation><nlm:affiliation>CHU Jean Minjoz, Radiotherapy Department, 25030 Besançon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lemanski, Claire" sort="Lemanski, Claire" uniqKey="Lemanski C" first="Claire" last="Lemanski">Claire Lemanski</name>
<affiliation><nlm:affiliation>Institut régional du Cancer de Montpellier, Radiotherapy Department, 34298 Montpellier, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De La Lande, Brigitte" sort="De La Lande, Brigitte" uniqKey="De La Lande B" first="Brigitte" last="De La Lande">Brigitte De La Lande</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 92210 Saint Cloud, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Baumann, Pierre" sort="Baumann, Pierre" uniqKey="Baumann P" first="Pierre" last="Baumann">Pierre Baumann</name>
<affiliation><nlm:affiliation>Centre d'Oncologie de Gentilly, Radiotherapy Department, 54 100 Nancy, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Missohou, Fernand" sort="Missohou, Fernand" uniqKey="Missohou F" first="Fernand" last="Missohou">Fernand Missohou</name>
<affiliation><nlm:affiliation>Centre Henri Becquerel, Radiotherapy Department, 76038 Rouen, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Levy, Christelle" sort="Levy, Christelle" uniqKey="Levy C" first="Christelle" last="Levy">Christelle Levy</name>
<affiliation><nlm:affiliation>Centre François Baclesse, Radiotherapy Department, 14000 Caen, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peignaux, Karine" sort="Peignaux, Karine" uniqKey="Peignaux K" first="Karine" last="Peignaux">Karine Peignaux</name>
<affiliation><nlm:affiliation>Centre Georges-François Leclerc, Département de radiothérapie, 21000 Dijon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bougnoux, Pierre" sort="Bougnoux, Pierre" uniqKey="Bougnoux P" first="Pierre" last="Bougnoux">Pierre Bougnoux</name>
<affiliation><nlm:affiliation>CHU Tours, Service de cancérologie, 37044 Tours, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Denis, Fabrice" sort="Denis, Fabrice" uniqKey="Denis F" first="Fabrice" last="Denis">Fabrice Denis</name>
<affiliation><nlm:affiliation>Centre Jean Bernard, Département de radiothérapie, 72000 Le Mans, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bollet, Marc" sort="Bollet, Marc" uniqKey="Bollet M" first="Marc" last="Bollet">Marc Bollet</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dendale, Remi" sort="Dendale, Remi" uniqKey="Dendale R" first="Rémi" last="Dendale">Rémi Dendale</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vago, Nora Ady" sort="Vago, Nora Ady" uniqKey="Vago N" first="Nora Ady" last="Vago">Nora Ady Vago</name>
<affiliation><nlm:affiliation>Roche, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Campana, Francois" sort="Campana, Francois" uniqKey="Campana F" first="François" last="Campana">François Campana</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fourquet, Alain" sort="Fourquet, Alain" uniqKey="Fourquet A" first="Alain" last="Fourquet">Alain Fourquet</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kirova, Youlia M" sort="Kirova, Youlia M" uniqKey="Kirova Y" first="Youlia M" last="Kirova">Youlia M. Kirova</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25260760</idno>
<idno type="pmid">25260760</idno>
<idno type="doi">10.1016/j.breast.2014.08.015</idno>
<idno type="wicri:Area/PubMed/Corpus">001291</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001291</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.</title>
<author><name sortKey="Pernin, Victor" sort="Pernin, Victor" uniqKey="Pernin V" first="Victor" last="Pernin">Victor Pernin</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Belin, Lisa" sort="Belin, Lisa" uniqKey="Belin L" first="Lisa" last="Belin">Lisa Belin</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Biostatistic Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Cottu, Paul" sort="Cottu, Paul" uniqKey="Cottu P" first="Paul" last="Cottu">Paul Cottu</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Oncology Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bontemps, Patrick" sort="Bontemps, Patrick" uniqKey="Bontemps P" first="Patrick" last="Bontemps">Patrick Bontemps</name>
<affiliation><nlm:affiliation>CHU Jean Minjoz, Radiotherapy Department, 25030 Besançon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lemanski, Claire" sort="Lemanski, Claire" uniqKey="Lemanski C" first="Claire" last="Lemanski">Claire Lemanski</name>
<affiliation><nlm:affiliation>Institut régional du Cancer de Montpellier, Radiotherapy Department, 34298 Montpellier, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="De La Lande, Brigitte" sort="De La Lande, Brigitte" uniqKey="De La Lande B" first="Brigitte" last="De La Lande">Brigitte De La Lande</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 92210 Saint Cloud, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Baumann, Pierre" sort="Baumann, Pierre" uniqKey="Baumann P" first="Pierre" last="Baumann">Pierre Baumann</name>
<affiliation><nlm:affiliation>Centre d'Oncologie de Gentilly, Radiotherapy Department, 54 100 Nancy, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Missohou, Fernand" sort="Missohou, Fernand" uniqKey="Missohou F" first="Fernand" last="Missohou">Fernand Missohou</name>
<affiliation><nlm:affiliation>Centre Henri Becquerel, Radiotherapy Department, 76038 Rouen, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Levy, Christelle" sort="Levy, Christelle" uniqKey="Levy C" first="Christelle" last="Levy">Christelle Levy</name>
<affiliation><nlm:affiliation>Centre François Baclesse, Radiotherapy Department, 14000 Caen, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peignaux, Karine" sort="Peignaux, Karine" uniqKey="Peignaux K" first="Karine" last="Peignaux">Karine Peignaux</name>
<affiliation><nlm:affiliation>Centre Georges-François Leclerc, Département de radiothérapie, 21000 Dijon, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bougnoux, Pierre" sort="Bougnoux, Pierre" uniqKey="Bougnoux P" first="Pierre" last="Bougnoux">Pierre Bougnoux</name>
<affiliation><nlm:affiliation>CHU Tours, Service de cancérologie, 37044 Tours, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Denis, Fabrice" sort="Denis, Fabrice" uniqKey="Denis F" first="Fabrice" last="Denis">Fabrice Denis</name>
<affiliation><nlm:affiliation>Centre Jean Bernard, Département de radiothérapie, 72000 Le Mans, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bollet, Marc" sort="Bollet, Marc" uniqKey="Bollet M" first="Marc" last="Bollet">Marc Bollet</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dendale, Remi" sort="Dendale, Remi" uniqKey="Dendale R" first="Rémi" last="Dendale">Rémi Dendale</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vago, Nora Ady" sort="Vago, Nora Ady" uniqKey="Vago N" first="Nora Ady" last="Vago">Nora Ady Vago</name>
<affiliation><nlm:affiliation>Roche, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Campana, Francois" sort="Campana, Francois" uniqKey="Campana F" first="François" last="Campana">François Campana</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Fourquet, Alain" sort="Fourquet, Alain" uniqKey="Fourquet A" first="Alain" last="Fourquet">Alain Fourquet</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kirova, Youlia M" sort="Kirova, Youlia M" uniqKey="Kirova Y" first="Youlia M" last="Kirova">Youlia M. Kirova</name>
<affiliation><nlm:affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Breast (Edinburgh, Scotland)</title>
<idno type="eISSN">1532-3080</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Angiogenesis Inhibitors (adverse effects)</term>
<term>Antibodies, Monoclonal, Humanized (adverse effects)</term>
<term>Bevacizumab</term>
<term>Breast Neoplasms (pathology)</term>
<term>Breast Neoplasms (therapy)</term>
<term>Carcinoma, Ductal, Breast (pathology)</term>
<term>Carcinoma, Ductal, Breast (therapy)</term>
<term>Carcinoma, Lobular (pathology)</term>
<term>Carcinoma, Lobular (therapy)</term>
<term>Chemoradiotherapy, Adjuvant (adverse effects)</term>
<term>Dermatitis (etiology)</term>
<term>Dyspnea (etiology)</term>
<term>Esophagitis (etiology)</term>
<term>Female</term>
<term>Fibrosis</term>
<term>Humans</term>
<term>Lymphedema (etiology)</term>
<term>Middle Aged</term>
<term>Neoadjuvant Therapy</term>
<term>Prospective Studies</term>
<term>Radiation Injuries (etiology)</term>
<term>Radiation-Sensitizing Agents (adverse effects)</term>
<term>Skin (pathology)</term>
<term>Telangiectasis (etiology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Radiation-Sensitizing Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Chemoradiotherapy, Adjuvant</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dermatitis</term>
<term>Dyspnea</term>
<term>Esophagitis</term>
<term>Lymphedema</term>
<term>Radiation Injuries</term>
<term>Telangiectasis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term>
<term>Carcinoma, Ductal, Breast</term>
<term>Carcinoma, Lobular</term>
<term>Skin</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term>
<term>Carcinoma, Ductal, Breast</term>
<term>Carcinoma, Lobular</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Bevacizumab</term>
<term>Female</term>
<term>Fibrosis</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Neoadjuvant Therapy</term>
<term>Prospective Studies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this multicenter prospective and descriptive study was to determine late toxicities and outcomes among patients with non-metastatic breast cancer receiving concurrent bevacizumab (BV) and radiation therapy (RT) in the clinical trials. Early and late toxicities were assessed and evaluation was available for 63 patients (pts) at 12 months. Acute radiation dermatitis was observed in 48 (76%): grade 1 for 27, grade 2 for 17 and grade 3 for 4 pts. Grade 2 acute oesophagitis was observed in one patient (2%). Little toxicity was described 1 year after the completion of RT: 7 pts (12%): grade 1-2 pain, 3 (5%) presented grade 1 fibrosis, and 2 pts (4%) - telangiectasia. One patient (2%) experienced grade 1 dyspnoea. Five grade 1-2 lymphoedema occurred. Only one patient experienced a LEVF value less than 50% one year after the end of RT. In conclusion, the concurrent BV with locoregional RT provides acceptable toxicities.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25260760</PMID>
<DateCreated><Year>2014</Year>
<Month>12</Month>
<Day>22</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3080</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>23</Volume>
<Issue>6</Issue>
<PubDate><Year>2014</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Breast (Edinburgh, Scotland)</Title>
<ISOAbbreviation>Breast</ISOAbbreviation>
</Journal>
<ArticleTitle>Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.</ArticleTitle>
<Pagination><MedlinePgn>816-20</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.breast.2014.08.015</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0960-9776(14)00164-7</ELocationID>
<Abstract><AbstractText>The purpose of this multicenter prospective and descriptive study was to determine late toxicities and outcomes among patients with non-metastatic breast cancer receiving concurrent bevacizumab (BV) and radiation therapy (RT) in the clinical trials. Early and late toxicities were assessed and evaluation was available for 63 patients (pts) at 12 months. Acute radiation dermatitis was observed in 48 (76%): grade 1 for 27, grade 2 for 17 and grade 3 for 4 pts. Grade 2 acute oesophagitis was observed in one patient (2%). Little toxicity was described 1 year after the completion of RT: 7 pts (12%): grade 1-2 pain, 3 (5%) presented grade 1 fibrosis, and 2 pts (4%) - telangiectasia. One patient (2%) experienced grade 1 dyspnoea. Five grade 1-2 lymphoedema occurred. Only one patient experienced a LEVF value less than 50% one year after the end of RT. In conclusion, the concurrent BV with locoregional RT provides acceptable toxicities.</AbstractText>
<CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pernin</LastName>
<ForeName>Victor</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Belin</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Biostatistic Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cottu</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Oncology Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bontemps</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>CHU Jean Minjoz, Radiotherapy Department, 25030 Besançon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lemanski</LastName>
<ForeName>Claire</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institut régional du Cancer de Montpellier, Radiotherapy Department, 34298 Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De La Lande</LastName>
<ForeName>Brigitte</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 92210 Saint Cloud, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Baumann</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Centre d'Oncologie de Gentilly, Radiotherapy Department, 54 100 Nancy, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Missohou</LastName>
<ForeName>Fernand</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Centre Henri Becquerel, Radiotherapy Department, 76038 Rouen, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Levy</LastName>
<ForeName>Christelle</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Centre François Baclesse, Radiotherapy Department, 14000 Caen, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peignaux</LastName>
<ForeName>Karine</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Centre Georges-François Leclerc, Département de radiothérapie, 21000 Dijon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bougnoux</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>CHU Tours, Service de cancérologie, 37044 Tours, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Denis</LastName>
<ForeName>Fabrice</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Centre Jean Bernard, Département de radiothérapie, 72000 Le Mans, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bollet</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dendale</LastName>
<ForeName>Rémi</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vago</LastName>
<ForeName>Nora Ady</ForeName>
<Initials>NA</Initials>
<AffiliationInfo><Affiliation>Roche, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Campana</LastName>
<ForeName>François</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fourquet</LastName>
<ForeName>Alain</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kirova</LastName>
<ForeName>Youlia M</ForeName>
<Initials>YM</Initials>
<AffiliationInfo><Affiliation>Institut Curie, Hospital, Radiotherapy Department, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Breast</MedlineTA>
<NlmUniqueID>9213011</NlmUniqueID>
<ISSNLinking>0960-9776</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011838">Radiation-Sensitizing Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003872" MajorTopicYN="N">Dermatitis</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004941" MajorTopicYN="N">Esophagitis</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011832" MajorTopicYN="N">Radiation Injuries</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011838" MajorTopicYN="N">Radiation-Sensitizing Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013684" MajorTopicYN="N">Telangiectasis</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword>
<Keyword MajorTopicYN="N">Concurrent bevacizumab</Keyword>
<Keyword MajorTopicYN="N">Radiotherapy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>05</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>08</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>08</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>9</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>9</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25260760</ArticleId>
<ArticleId IdType="pii">S0960-9776(14)00164-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.breast.2014.08.015</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001291 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001291 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:25260760
   |texte=   Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:25260760" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki